ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Our results showed that VK2 inhibited the proliferation of CML cell lines in a dose-dependent manner (IC50: K562, 4.5 μM; K562 PR, 5.5 μM; Ba/F3 BCR–ABL, 4.2 μM; Ba/F3 T315I, 8.3 μM) (Fig. 2C).